NCT01445301View on ClinicalTrials.gov

Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

September 27, 2011

Primary Completion Date

August 2, 2012

Study Completion Date

August 2, 2012

Conditions
Acne Vulgaris
Interventions
DRUG

GSK2585823(CLDM 1%-BPO 3% gel)

Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg

DRUG

CLDM 1% gel twice daily

Topical gel containing clindamycin 10 mg/1 g gel

Trial Locations (26)

273-0046

GSK Investigational Site, Chiba

002-8022

GSK Investigational Site, Hokkaido

003-0833

GSK Investigational Site, Hokkaido

004-0074

GSK Investigational Site, Hokkaido

004-0876

GSK Investigational Site, Hokkaido

006-0022

GSK Investigational Site, Hokkaido

060-0063

GSK Investigational Site, Hokkaido

062-0042

GSK Investigational Site, Hokkaido

064-0915

GSK Investigational Site, Hokkaido

066-0021

GSK Investigational Site, Hokkaido

066-0064

GSK Investigational Site, Hokkaido

069-0813

GSK Investigational Site, Hokkaido

090-0832

GSK Investigational Site, Hokkaido

093-0016

GSK Investigational Site, Hokkaido

211-0063

GSK Investigational Site, Kanagawa

221-0825

GSK Investigational Site, Kanagawa

532-0026

GSK Investigational Site, Osaka

559-0017

GSK Investigational Site, Osaka

572-0838

GSK Investigational Site, Osaka

593-8324

GSK Investigational Site, Osaka

350-1305

GSK Investigational Site, Saitama

111-0053

GSK Investigational Site, Tokyo

141-0031

GSK Investigational Site, Tokyo

150-0021

GSK Investigational Site, Tokyo

169-0075

GSK Investigational Site, Tokyo

194-0013

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01445301 - Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects | Biotech Hunter | Biotech Hunter